| Autor: |
Nandwani, R., Moyle, G. J., Perry, N., Hooker, M., Gazzard, B. G. |
| Předmět: |
|
| Zdroj: |
Journal of the European Academy of Dermatology & Venereology; Dec95, Vol. 5 Issue 3, p258-263, 6p |
| Abstrakt: |
Objective To report the development of giant pharyngeal ulcers in a series of HIV-positive patients after commencing zalcitabine therapy. We also present an algorithm for the clinical management of oral ulceration in HI V-infected individuals. Design and subjects Prospective review of patients who were prescribed zalcitabine. a nucleoside analogue reverse transcriptase inhibitor of HIV, at a single UK centre. Setting HIV out-patient clinic at the Chelsea and Westminster Hospital in London. Outcome measured Oro-pharyngeal ulceration associated with zalcitabine therapy. Results We report 3 cases of zalcitabine-associated oral toxicity which manifested as atypical giant pharyngeal ulcers. The subjects were all male homosexual non-smokers who were participating in the Medical Research Council Delta trial and had previously been randomised to receive didanosine or matching placebo in combination with zidovudine, before commencing open label zalcitabine. Conclusions Oral ulceration is a documented side-effect of zalcitabine, which may produce larger atypical lesions in some individuals. Possible predisposing factors and proposed mechanisms for zalcitabine-associated pharyngeal ulceration are discussed. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text